secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2024-09-04T23:59:59+00:00
Accession:  0001516551-24-000085
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience appoints Puneet Arora as Chief Medical Officer, grants 225,000 stock options
--------------------------------------------------------------------------------

- Puneet S. Arora, MD, appointed CMO effective Sept 3, 2024; base salary $475k with 40% target bonus.
- Received inducement stock option for 225k shares vesting over 4 years (25% at 1-year, then monthly).
- Previously CMO at Lassen Therapeutics, Head of Clinical Dev at Principia (Sanofi), Senior Medical Director at Genentech.
- Company focuses on Phase 2 CBeyond obesity trial for nimacimab, a CB1 inhibitor.
- Also granted 13,500 share non-qualified option to a new non-executive employee under inducement plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655124000085/0001516551-24-000085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655124000085/skye-20240903.htm
  HTML page:      https://secwatch.observer/filing/0001516551-24-000085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer